Ron Bentsur

Ron Bentsur has an estimated net worth of $77.8 Million. This is based on reported shares across multiple companies, which include Nuvectis Pharma, Inc., Beyond Air, Inc., UroGen Pharma Ltd., XTL BIOPHARMACEUTICALS LTD, KERYX BIOPHARMACEUTICALS INC, and STEMLINE THERAPEUTICS INC.

2022 was Ron Bentsur's most active year for acquiring shares with 46 total transactions. Ron Bentsur's most active month to acquire stocks was the month of April. 2020 was Ron Bentsur's most active year for disposing of shares, totalling 27 transactions. Ron Bentsur's most active month to dispose stocks was the month of July. 2022 saw Ron Bentsur paying a total of $2,103,449.68 for 480,000 shares, this is the most they've acquired in one year. In 2014 Ron Bentsur cashed out on 668,676 shares for a total of $9,521,780.63, their largest year based on trade value.